As of May 2016, *Clinical Psychopharmacology and Neuroscience* will encourage the use of Neuroscience-based Nomenclature (NbN) for all publications and correspondence. NbN has been developed to replace the current indication-based nomenclature and to provide a contemporary and useful framework for more scientific and better informed pharmacological decisions. Several other leading journals in the field, including *Biological Psychiatry*, *CNS Spectrums*, *European Psychiatry*, *International Journal of Neuropsychopharmacology*, *Neuropsychopharmacology*, and others have endorsed this nomenclature for its use in submissions.

The current nomenclature is based on clinical indications; for example, drugs used for mania and psychosis they are classified as "mood stabilizers" and "antipsychotic drugs", respectively. While this conventional nomenclature has been widely used in clinical as well as research settings, there are a number of limitations to this system. First, boundaries among various categories of psychotropic drugs, using the current nomenclature have become unclear. "Antipsychotic drugs" and "mood stabilizers" are good examples; antipsychotic drugs are used for not only schizophrenia, but also mood disorders, including bipolar disorder and treatment resistant depression. On the other hand, mood stabilizers are often prescribed for a mood component in any psychiatric disorder. This discrepancy between their names and indications often confuses patients and their caregivers and sometimes leads to a misunderstanding of the effects of prescribed medications. Second, up-to-date scientific knowledge on these drugs has not been reflected in the current nomenclature. This is a serious issue since the current system was created nearly half a century ago. For example, dopamine receptor antagonists and a partial dopamine receptor agonist are currently included in the same category of "antipsychotic drugs" despite the difference in their drug profiles. Moreover, the involvement of the serotonergic system also has to be considered for some drugs. However, such differences are not reflected in the current system.

To overcome these limitations of the current nomenclature, following an initiative of the European Congress of Neuropsychopharmacology (ECNP), a taskforce for psychotropic nomenclature was established with representatives from 5 international organizations: the ECNP, Asian College of Neuropsychopharmacology (AsCNP), American College of Neuropsychopharmacology (ACNP), International College of Neuropsychopharmacology (CINP), and International Union of Basic and Clinical Pharmacology (IUPHAR). The mission of this taskforce is to provide a pharmacologically-driven (rather than indication-based) nomenclature that embeds contemporary neuroscience understanding of how medicines act, to help clinicians to make informed choices when they are trying to figure out what would be the next "pharmacological step", and to decrease stigma and enhance adherence by a naming system that lays out the rationale for selecting a specific psychotropic.[@b1-cpn-14-115],[@b2-cpn-14-115]

In the first edition of the NbN, 108 psychotropics are included. The NbN provides a pharmacological driven nomenclature focusing on pharmacology and mode of action, which reflects current knowledge and understanding about the targeted neurotransmitter, molecule, system being modified, and mode/mechanism of action. It also includes 4 additional dimensions: (1) approved indications, (2) efficacy and side effects, (3) "practical note" which summarizes the clinical knowledge that has been prioritized by "filtering" though the taskforce's "opinion sieve", and (4) neurobiology.[@b3-cpn-14-115] The easiest and recommended way to access the newest version of the NbN is to use the approved app, which is freely available on the project's website (<http://nbnomenclature.org/>). In this website, there is a special tag - For Authors, too.[@b3-cpn-14-115]

The NbN project has just started. Taking into account new findings and new insights, including feedback from users, the NbN will be updated on a yearly basis. Since it always needs time to change the culture, we understand the transition will likely involve some expected and unexpected responses from the field. However, we rather believe that such responses and feedback will surely improve the quality of the NbN, which in turn will be beneficial for clinicians, researchers, patients as well as their caregivers.
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